Program
NNC0497-0040
A development code.
Its studies are mostly in Diabetes Mellitus, Type 1, led by Novo Nordisk.
Furthest: phase 1, since May 5, 20261 company-led study, 1 open or runningNext primary completion: Feb 18, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 11 open or running | phase 1since May 5, 2026 | May 5, 2026 | Feb 18, 2028phase 1 · NCT07578584 |
- Named in Novo Nordisk’s own pipeline as
NNC0497-0040 (diabetes)
, phase 1, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2026First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT07578584 · 146 planned · Germany
Ahead
- Feb 18, 2028Primary completion: phase 1 study in Diabetes Mellitus, Type 1NCT07578584
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07578584Diabetes Mellitus, Type 1 · Germany | 1 | Recruiting | Feb 18, 2028 | 146 |
How it is read
Names in the registry
- “NNC0497-0040”, 1 entry
Codes read as this program: NNC04970040.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.